Ballenger J C
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425.
J Psychiatr Res. 1990;24 Suppl 2:15-25. doi: 10.1016/0022-3956(90)90032-l.
Until recently, the benzodiazepines were believed to be ineffective in the treatment of panic disorder, with and without agoraphobic avoidance. Recent trials have shown, however, that panic disorder patients respond to benzodiazepines as well as to tricyclic antidepressants and monoamine oxidase (MAO) inhibitor antidepressants. Most of the controlled-trial investigations of benzodiazepines in panic disorder patients have evaluated the effects of alprazolam. However, early uncontrolled trials using other benzodiazepines have documented their effectiveness in panic disorder as well. This article reviews the evidence of the efficacy of alprazolam and other benzodiazepines in the treatment of panic disorder and their clinical use.
直到最近,人们还认为苯二氮䓬类药物对伴或不伴有广场恐怖回避的惊恐障碍治疗无效。然而,最近的试验表明,惊恐障碍患者对苯二氮䓬类药物的反应与对三环类抗抑郁药和单胺氧化酶(MAO)抑制剂抗抑郁药的反应一样。大多数针对惊恐障碍患者使用苯二氮䓬类药物的对照试验研究都评估了阿普唑仑的效果。不过,早期使用其他苯二氮䓬类药物的非对照试验也证明了它们在惊恐障碍治疗中的有效性。本文综述了阿普唑仑和其他苯二氮䓬类药物治疗惊恐障碍的疗效证据及其临床应用。